storage and handling

Indications

Adjuvant Breast Cancer

KANJINTI® is indicated for adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with one high-risk feature*)…Read more breast cancer:

KANJINTI® is indicated for adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with one
high-risk feature*) breast cancer…Read more:

As part of a treatment regimen containing doxorubicin, cyclophosphamide and either paclitaxel or docetaxel
As part of treatment with docetaxel and carboplatin
As a single agent following multi-modality anthracycline-based therapy

Select patients for therapy based on an FDA-approved companion diagnostic for trastuzumab product.

*High-risk is defined as ER/PR positive with one of the following features: tumor size > 2 cm, age < 35 years, or tumor grade 2 or 3.

Metastatic Breast Cancer

KANJINTI® is indicated:

In combination with paclitaxel for the first line treatment of HER2-overexpressing metastatic breast cancer
As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease

Select patients for therapy based on an FDA-approved companion diagnostic for trastuzumab product.

Metastatic Gastric Cancer

KANJINTI® is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with
HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment
for metastatic disease.

Select patients for therapy based on an FDA-approved companion diagnostic for trastuzumab product.

KANJINTI® has an established
Q-code: Q5117

Amgen has achieved zero supply shortages in the last decade.

*Multi-dose when reconstituted with Bacteriostatic Water for Injection.

†420 mg multi-dose kit contains one multiple-dose vial of KANJINTI® and one vial (20 mL) of Bacteriostatic Water for Injection (BWFI), USP, containing 1.1% benzyl alcohol as a preservative.

‡Current as of September 2022.

§EU-sourced Herceptin® was used in the LILAC study. The KANJINTI® clinical pharmacokinetic (PK) study demonstrated equivalence between EU- and US-sourced Herceptin® and KANJINTI®.

Indications

Adjuvant Breast Cancer

Metastatic Breast Cancer

Metastatic Gastric Cancer

Important Safety Information

Important Safety Information

Additional Important Safety Information

Indications

BEHIND KANJINTI®

IDENTICAL STORAGE AND HANDLING1

Connect with an Amgen Oncology representative

Privacy Statement

BEHIND KANJINTI^®

IDENTICAL STORAGE AND HANDLING¹